Bladder Wall Blood Perfusion Pattern and Sexual Dysfunction in Female Patients With Lower Urinary Tract Symptoms, and the Association of That Perfusion Pattern and Therapeutic Efficacy of Antimuscarincs for Female Overactive Bladder Syndrome.

This study is currently recruiting participants. (see Contacts and Locations)
Verified February 2016 by Far Eastern Memorial Hospital
National Science Council, Taiwan
Information provided by (Responsible Party):
Sheng-Mou Hsiao, Far Eastern Memorial Hospital Identifier:
First received: January 23, 2011
Last updated: February 22, 2016
Last verified: February 2016
Overactive bladder syndrome (OAB) affects around 17 % of female population. However, the etiology of OAB is complicated and unclear in many aspects. Bladder wall thickness had been reported to be strongly associated with OAB, but its use as a screening tool remains controversial. Besides, few studies reported patterns of sexual dysfunction in female patients with lower urinary tract symptoms (LUTS). Therefore the aims of our study were to analyze the bladder wall blood perfusion pattern in female LUTS patients, the association of between the bladder wall blood perfusion pattern and the efficacy of anti-muscarinic treatment for female OAB, and the patterns of sexual dysfunction in the female LUTS patients.

Condition Intervention
Lower Urinary Tract Symptoms
Drug: Tolterodine SR

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Far Eastern Memorial Hospital:

Primary Outcome Measures:
  • Blood flow pattern after antimuscarinics [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Blood flow patterns between different LUTS subgroups [ Time Frame: 1 day ] [ Designated as safety issue: No ]

Estimated Enrollment: 300
Study Start Date: July 2010
Estimated Study Completion Date: December 2016
Estimated Primary Completion Date: December 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Bladder wall blood perfusion pattern Drug: Tolterodine SR
Tolterodine SR 4 mg qd


Ages Eligible for Study:   20 Years to 99 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • all cases are female patients with lower urinary tract symptoms

Exclusion Criteria:

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01282840

Far Eastern Memorial Hospital Recruiting
Pan-Chiao, Taiwan
Contact: Hsiao Sheng Mou, MD    +886-2-89667000 ext 124   
Sponsors and Collaborators
Far Eastern Memorial Hospital
National Science Council, Taiwan
  More Information

Responsible Party: Sheng-Mou Hsiao, Chief, Department of Obstetrics & Gynecology, Far Eastern Memorial Hospital Identifier: NCT01282840     History of Changes
Other Study ID Numbers: 099049-F 
Study First Received: January 23, 2011
Last Updated: February 22, 2016
Health Authority: Taiwan: Institutional Review Board

Keywords provided by Far Eastern Memorial Hospital:

Additional relevant MeSH terms:
Lower Urinary Tract Symptoms
Signs and Symptoms
Urological Manifestations
Tolterodine Tartrate
Cholinergic Agents
Cholinergic Antagonists
Molecular Mechanisms of Pharmacological Action
Muscarinic Antagonists
Neurotransmitter Agents
Physiological Effects of Drugs
Urological Agents processed this record on May 23, 2016